Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "nhibition of established collagen-induced arthritis with a tumour α necrosis factor-α inhibitor expressed from a self-contained doxycycline regulated plasmid"
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Inhibition of established collagen-induced arthritis with a tumour α necrosis factor-α inhibitor expressed from a self-contained doxycycline regulated plasmid. | Available online http arthritis-research.eom content 6 2 R103 Research article Open Access Inhibition of established collagen-induced arthritis with a tumour necrosis factor-a inhibitor expressed from a self-contained doxycycline regulated plasmid David J Gould Carly Bright and Yuti Chernajovsky Bone Joint Research Unit Barts and The London Queen Mary s School of Medicine and Dentistry University of London London UK Corresponding author Yuti Chernajovsky e-mail y.chernajovsky@qmul.ac.uk Received 18 Sep 2003 Revisions requested 14 Oct 2003 Revisions received 27 Nov 2003 Accepted 28 Nov 2003 Published 22 Dec 2003 Arthritis Res Ther 2004 6 R103-R113 DOI 10.1186 ar1036 2004 Gould et al. licensee BioMed Central Ltd Print ISSN 1478-6354 Online ISSN 1478-6362 . This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Tumor necrosis factor TNF -a is produced by cells of the immune system and is a key mediator in immune and inflammatory reactions. Through interaction with widely expressed receptors TNF receptor 1 and TNF receptor 2 TNF-a is able to orchestrate the expression of a range of downstream proinflammatory molecules. Over the past decade novel biologics that inhibit TNF-a have been developed as extremely effective treatments for rheumatoid arthritis. Structurally these biologics are antibodies or TNF receptors on an antibody backbone that bind TNF-a directly and are delivered to patients by repeated injection. Gene therapy offers an improved approach to delivering biologics as a single administration of their encoding genetic material. In the present study we demonstrate the therapeutic effect of a small molecular weight dimeric TNF receptor 2 dTNFR constitutively expressed from plasmid DNA delivered intramuscularly with electroporation after disease onset in a collagen-induced arthritis model. Regulated promoters .